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Abstract: Surface-Enhanced Raman Spectroscopy (SERS) is a label-free technique that enables
quick monitoring of substances at low concentrations in biological matrices. These advantages
make it an attractive tool for the development of point-of-care tests suitable for Therapeutic Drug
Monitoring (TDM) of drugs with a narrow therapeutic window, such as chemotherapeutic drugs,
immunosuppressants, and various anticonvulsants. In this article, the current applications of SERS in
the field of TDM for cancer therapy are discussed in detail and illustrated according to the different
strategies and substrates. In particular, future perspectives are provided and special concerns
regarding the standardization of self-assembly methods and nanofabrication procedures, quality
assurance, and technology readiness are critically evaluated.
Keywords: SERS; TDM; drug monitoring; Individualized cancer chemotherapy
1. Introduction
1.1. Therapeutic Drug Monitoring (TDM)
Therapeutic drug monitoring (TDM) has been used in clinical practice since the beginning
of the 1970s, and it is now routinely required for a small fraction of drugs (~30) used in
pharmacotherapy [1]. For these drugs (e.g., antiepileptics, immunosuppressants, anti-HIV agents,
anticonvulsants, some antibiotics, and some cytotoxic drugs), such monitoring is essential to provide
patients with effective treatment, while minimizing drug toxicity and minimizing the risk of adverse
drug reactions. More recently, cancer therapy has become a burgeoning field for the development of
novel analytical procedures for less frequently monitored drugs [2]. Personalized medicine has been
increasingly advocated to improve the standard of care for oral/new molecularly targeted therapeutics,
where side effects can be substantial and life threatening. However, TDM is seldom performed in
clinical oncology due to cost/time considerations, analytical issues, and the lack of point-of-care
instrumentation available [3–6].
TDM, in practice, involves assessing drug concentration in a biological matrix (most commonly
plasma or serum) at a known time related to administration, and interpreting these concentrations in
terms of relevant clinical parameters (target range, pharmacokinetics of the drug) [7]. Only a small
fraction of prescription drugs requires TDM because, for the majority of drugs, there is a wider
difference between the minimum effective concentration and the toxic concentration (therapeutic
index). Thus the dose is easily adjusted by empirically assessed pharmacodynamic parameters
(titration to clinical effect) [8,9]. TDM is required for drugs with a narrow therapeutic index when:
(i) it is hard to correlate therapeutic or low toxicity levels with clinical effects alone; (ii) the relationship
between the drug dose and serum concentration is highly variable and/or not predictable; (iii) there is
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a clear correlation between serum concentration of the drug and its therapeutic response or toxicity;
(iv) serious consequences for under- or overdosing may be avoided by TDM [8,10].
Most of the analytical platforms commonly used for TDM in clinical practice rely on many different
immunoassays, or on separation techniques coupled with mass spectrometry (MS). The fundamentals
and application of these platforms will not be discussed in this review but have been extensively
reported elsewhere [11,12]. A brief summary is reported in Table 1. In general, immunoassays are
routine methods due to the ease of operation and speed, but they carry many limitations, such as
interferences from components of matrices, drug metabolites, structurally similar drugs, as well
as endogenous compounds. In addition, they are not available for all drugs currently monitored.
On the other hand, reference methods such as liquid chromatography combined with tandem mass
spectrometry (LC-MS/MS) are in some cases still the gold standard for TDM in clinical laboratories,
because they are analytically more robust and relatively free from interferences. However, the analysis
is time-consuming and labor-intensive, due to the extensive sample preparation and significant volume
of samples needed for processing the biofluids.
Since the infrastructure required for TDM on chromatographic, mass spectrometric,
and immunoassay techniques is expensive and not necessarily available in small hospitals, methods
such as surface plasmon resonance (SPR) [13], localized SPR [14], electrochemical sensors [15],
and quartz crystal microbalance (QCM) [16], have recently been proposed as potential TDM platforms
able to provide a rapid response with limited infrastructure and sample preparation. However,
the listed methods feature biofouling problems while performing the measurements, preventing
their use for routine, large-scale testing. In fact, nonspecific binding of unwanted proteins and other
molecules onto the sensing interface of devices can easily foul the active surface of the biosensors,
thus generating overwhelming background signal and preventing the detection of target drugs [17,18].
In spite of the amount of research recently dedicated to the protection against fouling agents, this issue
is still not fully resolved to date [19]. Therefore, new techniques, that are cheaper and faster than the
current reference methods, are still sought which could be regularly and easily used in hospitals.
Table 1. Pros and cons of analytical techniques currently used in TDM, compared with SERS.
Technique Description Pros Cons
Chromatography-
based methods
GC-MS/MS
LC-MS/MS
Chromatography separates
individual compounds by their
physical or chemical interaction
with an immobile material.
Once separated, combined selective
MS techniques provide mass-based
identification of the compounds
Gold standard;
Robust methods with superior
sensitivity and sensibility;
Relatively free from interferences;
Multiplexing capabilities;
Reduced drug class/metabolites
cross reactivity
Time consuming;
Laboratory-developed tests;
Interlaboratory variability;
Matrix effects;
High technical expertise required;
High costs for installation, personnel training,
and method validation;
Need for sample clean-up
Immunoassay platforms
ACMIA, CEDIA,
CMIA, ELISA, EMIT,
FPIA, MEIA, PETNIA
Analyte is detected by its binding
with a specific binding molecule,
which in most cases is an
analyte-specific antibody
Small amount of sample (<100 µL);
Run on automated, continuous,
random access systems;
No need for sample clean-up;
Multiplexing capabilities
Several steps to achieve quantification of the analyte;
Reduced specificity and sensitivity;
Often show significant bias;
Antibody cross-reactivity;
Interferences from bilirubin, hemoglobin, high
lipid content, very high or very low protein
content, endogenous antibodies, various drugs
and metabolites
SERS-based methods
Inelastic light scattering on molecule
adsorbed on the roughened metal
surface is measured
No need for sample preparation;
Fast measurement;
Multiplexing capabilities;
Availability of portable
Raman spectrometer
Very often high RSD of the SERS substrates;
method optimization needed for each drug;
GC-MS/MS, Gas Chromatography-tandem Mass Spectrometry; LC-MS/MS, Liquid Chromatography-tandem
Mass Spectrometry; ACMIA, Antibody Conjugated Magnetic Immunoassay; CEDIA, Cloned Enzyme
Donor Immunoassay; CMIA, Chemiluminescent Microparticle Immunoassay; ELISA, Enzyme-linked
Immunosorbent Assay; EMIT, Enzyme Multiplied Immunoassay Technique; FPIA, Fluorescence Polarization
Immunoassay; MEIA, Microparticle Enzyme Immunoassay; PETNIA, Particle-Enhanced Turbidimetric
Inhibition Immunoassay; RSD, Relative Standard Deviation.
Surface-enhanced Raman spectroscopy (SERS) could also be a good candidate for TDM since,
in principle, quantitative analyses of drugs in body fluids could be made within a few minutes and with
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comparable or smaller errors than routine TDM methods [20–22]. Although SERS shares with other
methods (e.g., SPR, QCM) the problem of surface fouling, the higher amount of information present in
SERS spectra makes it easier to exploit the full potential of multivariate data analysis (see Section 1.4)
to limit the interference of non-specific binding. Additionally, portable Raman spectrometers are
available nowadays, which are robust, small, and easy to use: therefore, they could be routinely used
in clinical settings by non-specialized operators.
This review summarizes the prospective applications of SERS in the field of TDM for cancer
therapy. We will compare the critical issues concerning preparation, sensitivity, and selectivity of
proposed approaches, and we will discuss the direction presently taken by the techniques.
1.2. Surface Enhanced Raman Spectroscopy (SERS)
In 1974, Fleischmann et al. [23] discovered that molecules of pyridine adsorbed on specially
prepared silver surfaces produced a Raman spectrum that was several orders of magnitude more
intense than expected [24]. This effect came to be known as Surface Enhanced Raman Spectroscopy
(SERS). In 1977, the discovered phenomenon enabled studies on kinetic processes of amines that
occured during their adsorption at the silver electrodes [25]. Increases in the intensity of the Raman
signal on the order of 104–106 have been regularly observed, first calculated by M. Albrecht and
J. Creighton with the example of pyridine at silver electrodes [26] , and the enhancement can be
as high as 1010–1012 for some systems [27]. The largest contribution to the intensity amplification
results from the so-called “electromagnetic mechanism”, postulated by Van Duyne as ‘an electric field
enhancement’ [25], in which the electric field is locally enhanced in the vicinity of nanostructured metal
surfaces that are illuminated with light resonant with the localized surface plasmon frequency of the
metal structure [24]. The electromagnetic mechanism allows for the occurrence of a SERS effect even in
those cases in which analytes are not directly adsorbed on the metal, but are within a few nanometers
from it. Besides the electromagnetic mechanism, for molecules chemisorbed on a SERS-active surface
there is also a “chemical mechanism”, which involves the creation of new molecular states because of
the direct interaction with the metal, in addition to the electromagnetic effect [25,26]. The occurrence of
a SERS effect has been demonstrated with many molecules and with some metals, i.e., mainly copper,
silver, and gold, although minor enhancements have also been demonstrated for lithium, sodium,
potassium, indium, platinum, and rhodium [24]. SERS signals strongly depend on the type of the metal
surface, which influences the presence of ‘hot spots’, defined as “highly localized regions of intense
local field enhancement caused by surface plasmon resonance, usually occurring within interstitial
crevices in metal structures” [28].
Many techniques can be used to produce SERS substrates, i.e., metallic nanostructures capable of
inducing a SERS effect [22]. Here we decided to use a general classification of the substrates: metallic
nanoparticles dispersed in a liquid medium (colloidal substrates), solid non-colloidal substrates,
and “hybrid” substrates (in which the two previous substrate types are used in synergy). Colloidal
dispersions are the easiest to prepare but usually require partial aggregation, which can be induced
by the addition of an electrolyte such as KNO3 or NaCl [29,30], to form SERS-effective metal
nanostructures. However, nanostars or other nanoparticles with non-spheroidal shapes may show
a significant SERS effect, even in the absence of aggregation.
1.3. Critical Issues on the Use of SERS for TDM
TDM depends heavily on the ability to measure drug concentrations in a body fluid, most
commonly serum, plasma, or whole blood. In general, several intrinsic difficulties can complicate the
quantification as well as identification of analytes with SERS. First of all, an absolute SERS signal is
very difficult to achieve since Raman scattering intensity can fluctuate due to various experimental
conditions, such as pH conditions, laser wavelength and power, and the optical alignment of the
instrument. Thus, a fine control of those factors is crucial for reliable quantitative measurements [31,32].
Secondarily, qualitative variations within the SERS substrate can affect the hot spots distribution and
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efficiency, making it difficult to reproduce the signal even for the same sample [33]. The use of internal
standards has been recently proposed as a possible solution for this problem [34,35].
While SERS is expected to provide quantification of a specific target analyte in complex biofluids,
in practice several drugs can be detected and quantified in simple solutions, but the presence of
other biomolecules severely interferes with the SERS spectra, making quantification in real samples
a challenging task. Clinical samples are complex mixtures containing lipids and proteins that can bind
to the drug of interest. The reference interval for total serum protein is 60–80 g/L [36], while target
drugs are present at considerably lower concentrations (usually ng/L). Consequently, only a fraction
of the drug molecules will be free to interact with the metal surface, and thus to benefit from
the signal enhancement. Then, even free, unbound analytes must compete for adsorption with
the sample constituents, in order to be detected. Human serum, for instance, contains more than
4000 metabolites [37], some of which have a high affinity for metal surfaces, as proven by the intense
SERS signal given by serum when using metal colloids [38].
Therefore, several authors have focused on obtaining SERS signals from biological samples under
controlled experimental conditions, aimed at simplifying the chemical complexity of the sample itself,
in the bulk or at the metal surface [39]. This simplification could be achieved, for instance, either
through the integration of SERS with separation techniques or via the functionalization of the SERS
substrates with selective recognition elements, hence ensuring specificity for an analyte of interest
while minimizing the interference from other biochemical species present in the sample.
Many separation technologies, like thin layer chromatography (TLC) [40] and capillary
electrophoresis [41], have been coupled with SERS to separate the analytes from interfering species
before SERS detection. Further improvements aimed at physically integrating many complex devices
or functions in small instruments (e.g., lab-on-a-chip approaches), working with a high degree of
automation, will be of tremendous importance for future clinical implementations of SERS.
An alternative way to efficiently separate the target analytes from the matrix components is the
modification of the metal surface, directly or via a short linker moiety, with specific recognition elements
(also called “artificial receptors”), such as macrocyclic host molecules, small peptides, or molecularly
imprinted polymers (MIPs), to promote the selective surface binding of particular analytes [42].
Another issue, often underestimated, to be carefully considered in SERS measurements, is the
choice of the laser wavelength. This parameter will affect results in at least three ways.
First, the laser should be able to efficiently excite the localized surface plasmons of the SERS
substrates used.
Secondly, when the laser wavelength falls within an electronic transition band of the analyte,
a Resonance Raman (RR) effect will add to the SERS effect, yielding a so-called surface-enhanced
resonance Raman scattering (SERRS) spectrum. SERRS ensures a greater enhancement which is
selective with respect to the resonant analyte, thus partially solving the problems due to spectral
interference of other components. The SERRS effect can be exploited for all those drugs which absorb
in the visible region, such as doxorubicin [43,44] or mitoxantrone [45]. However, biomolecules naturally
present in many biofluids, such as carotenoids, also absorb in the visible region, yielding intense SERRS
bands which may interfere with drug detection.
A third aspect, related to the excitation wavelength, concerns the spectral interference of
fluorescence due to endogenous fluorophore species present in biofluids. All these aspects have
been discussed in a recent review about SERS of biofluids [38], and since they can positively or
negatively impact the results, they must be carefully considered when designing an experimental
approach for a SERS quantification of a drug in biofluids.
1.4. Quantification with SERS: The Role of Data Analysis
To monitor the concentration of a certain drug in biofluids, it is necessary to build a model,
as a calibration curve, through which it is possible to extrapolate the information about the
concentration of the drug from SERS spectra. However, a typical SERS spectrum can be rather
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complex, consisting of a large number of variables (p, i.e., Raman shifts), typically on the order of
1000 or more, even when the number of samples (n) is relatively small (causing the so-called large p,
mall n problem) [46].
In a univariate calibration, known concentrations of reference standards are assembled. Single
intensities (or integrated areas) are plotted against drug concentrations and the pertinent calibration
is the result of a regression, relating a measured intensity (or integrated area) value to the drug
concentration [47]. Although univariate calibration is the most intuitive and simple situation,
its application requires both a high signal-to-noise ratio (S/N) and an instrumental response,
which depends only on the concentration of the analyte of interest. Interferences from biofluid
constituents may contribute to the measured intensity at a specific Raman shift, making it arduous to
differentiate an analyte-specific signal from an interfering one, when considering only one point in the
data spectrum.
An alternative that may overcome most of the limitations of univariate calibration is a multivariate
calibration, which uses multiple responses simultaneously (e.g., the response at a range of Raman
shifts, or over the entire range collected), to calculate concentrations. Spectral data are treated
using chemometric tools, mainly by the application of regression techniques. The advantage over
univariate methods lies in a higher accuracy due to the inclusion of more spectral information and less
noise [48–50].
Various methods have been developed for building a multivariate calibration model, each of
which aims to simplify complex spectroscopic information. While a comprehensive description of these
methods is beyond the scope of this paper, many examples of applications to a wide range of studies
can be found in the literature [47,51,52]. The technique most widely used in combination with SERS is
partial least squares regression (PLSR), which manages the data with more variables than samples by
replacing the original variables with a few latent variables (LVs) [53]. Many popular variants of the
PLSR algorithm are available and, in some works, hybrid methods which use a combination of two or
more statistical tools (such as, for example, elastic net (EN) or principal component analysis (PCA))
have been employed to extract relevant chemical information before applying the PLSR [54,55].
Spectral data pre-processing procedures (involving fluorescence background/cosmic ray artefacts
removal, outlier rejection, dimensionality reduction) have a strong influence on the outcome of
the subsequent quantitative analysis [56]. “Appropriate” pre-processing combinations can enhance
the model, increasing its accuracy and lowering the error of prediction, while “not appropriate”
combinations can introduce a decline of the model performance [57]. These factors must be taken into
account during the development of any multivariate data analysis.
A reliable application of SERS for TDM routine analysis requires (i) an appropriate validation
of the regression model to avoid overfitting; and (ii) the establishment of figures of merit (FOMs) to
certify the prediction ability and define the quality of the analytical method [58,59]. Concerning the
first point, there is a general consensus about the fact that the only sure way to prove a model’s
robustness is to use an independent test set, which contains only data from samples that were not
used in the previous generation/optimization of the model [60]. However, when the number of
samples is too small to construct a proper independent test set, more sophisticated methodologies
using resampling/bootstrapping nested procedures, such as Repeated Double Cross-Validation [61,62],
are considered as suitable alternatives. Concerning the FOMs needed for an analytical method to
meet the regulatory requirements moving from the laboratory scale to the clinical level, some relevant
guidelines are already available (see, for instance, 2002/657/EC [63], ISO 11843 [64], and IUPAC [65]).
FOMs concepts include selectivity, specificity, linearity response, accuracy (trueness and precision),
reproducibility, decision limit (CCα, former limit of detection, LOD), and detection capability (CCβ,
nowadays preferred to the more known limit of quantification, LOQ). It must be noted that while the
reporting of FOMs is straightforward and well defined for univariate calibrations, the evaluation of
FOMs in multivariate calibrations is much more difficult and controversial [47,66].
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2. Applications of SERS Relevant to TDM
The papers published so far reported results from measurements performed in body fluids
(serum, saliva, blood, plasma, urine, vein/muscle), in surrogate matrices mimicking body fluid
conditions (buffered solutions of bovine serum albumin (BSA), or human serum albumin (HSA)),
and in water/inorganic solvents (Table 2). Only one publication describes experiments performed on
clinical samples from patients treated with mitoxantrone [45]. For a better comparison, the papers
considered in this review were grouped according to the type of the SERS substrates used (colloidal,
non-colloidal, and hybrid substrates, as already mentioned).
Table 2. Overview of research involving SERS for TDM of various type of chemotherapeutic drugs.
Sample Drug SERS Substrate Laser Line (nm) LOD (M) Calibration Refs.
Clinical sample
serum Mitoxantrone Ag colloid FLOW 514633 4 × 10
−11 b U [45]
Spiked body fluid
saliva 5-FU SERS-activecapillaries 785 1.15 × 10
−06 a U [67,68]
blood 6-MP Si-AuNPsneedles 785 n.r. n.r. [69]
bovine plasma Doxorubicin Ag colloid 488 n.r. M [70]
plasma Imatinib Au on glass with Al 785 n.r. n.r [71]
human serum MTX Au colloid on paper 785 n.r. M [54]
blood plasma Paclitaxel Au-polystyrene beads 785 n.r. M [72]
Surrogate matrix
1.5% HSA-PBS Irinotecan Ag and Au colloid onTLC plate
514
785 n.r. n.r. [40]
1% BSA-PBS MTX Sandwich substrate 532 10−09 b n.r. [73]
0.6% HSA Paclitaxel Ag colloid 532 n.r. n.r. [74]
Other solutions
water 6-MP β-CD AgNPsAg colloid 785
2.4 × 10−09 a
1.4 × 10−08 a U [75]
water MTX Ag-graphene 785 6 × 10−10 b U [76]
water Imatinib Au on glass with Al 785 n.r. n.r. [71]
water Mitoxantrone PNA 785 4.18 × 10−08 c U [77]
BRB (pH 2.0) 6-MP GO/AgNP hybrids 532 1.05 × 10−07 b U [78]
MeOH
Irinotecan
SN-38
Sunitinib
Klarite™ 633
34–40 *,e
11–28 *,e
11–15 *,e
U [79]
150 nM KOH MTX Ag colloid FLOW CELL 514785 1.70 × 10
−07 b U [80]
DMSO Paclitaxel GNC UV-NIL 633 10−09 f U [81]
β-CD—β-Cyclodextrin; 5-FU—5-fluorouracile; 6-MP—6-mercaptopurin; BRB—Britton-Robinson Buffer;
BSA—bovine serum albumin; GNC—gold nanocylinder; GO/MNP—graphene oxide/silver nanoparticles;
HAS—human serum albumin; KOH—potassium hydroxide; M—multivariate; MTX—Methotrexate; n.r.—not
reported; PNA—plasmonic nanodome array; U—univariate. * ng/mm2; a LOD is three times the signal-to-noise
ratio; b LOD calculation not defined; c LOD is three times the standard deviation of five blank intensities;
d LOD is three times the background noise; e LOD is the lower amount of analyte clearly identified above the
noise; f LOD is 3σ/k with σ as the standard deviation of blank measures and k as the slope of the calibration
plot (IUPAC).
2.1. Colloidal Substrates
Colloidal nanoparticles are the most commonly used substrates in SERS because of their relatively
low cost and ease of preparation. To the best of our knowledge, so far there are two publications that
successfully perform SERS measurements by directly adding colloidal silver nanoparticles (AgNPs)
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to the sample; detection of doxorubicin and paclitaxel in bovine plasma (BP [70]) and human serum
albumin (HSA) solution [74], respectively.
In the case of doxorubicin [70], AgNPs were activated with sodium chloride (NaCl) and
doxorubicin solutions were prepared in 1% bovine plasma. The calibration curve showing the
dependence of the intensity of the SERS signal on the analyte concentration was reported in
a concentration range between 100 and 750 nM. In this case, the SERS technique presents a detection
limit at much higher concentrations with respect to the reference methods (e.g., for HPLC-MS and
CE-LIF, LOD is around 1–2 nM). However, it is important to note that the measurements did not
require any sample pre-treatment, unlike chromatographic or electrophoretic measurements. Paclitaxel
detection with SERS on colloids was shown in a preliminary report, where AgNPs activated with
sodium nitrate (NaNO3) were used as substrates in HSA solutions [74]. The lowest concentration
detected of paclitaxel, at different pH values, was 10−5 M.
Colloidal metal nanoparticle dispersions can also be modified with additional nanostructures
(achieving so-called “hybrid” nanoparticles) to enhance their SERS performance. Recently,
graphene-modified surfaces have gained increasing popularity as SERS substrates due to their
stability, and to the enhancement and repeatability of the SERS signal. Successful determination
of 6-mercaptopurine (6-MP) in tablets was performed with the use of graphene-modified metal
nanoparticles [78]. In this work, hybrids of graphene oxide (GO) and metal nanoparticles (MNPs)
through the mediation of polyethyleneimine (PEI) molecules were used. For the quantification of
this drug in pharmaceutical tablets, SERS results using these hybrid nanoparticles did not show
significant differences when compared to the standard UV-Vis measurements, indicating the potential
of the method.
Another possible approach is to modify the nanoparticles with molecules that can mediate
the interaction with the analyte. Yang et al. [75] have shown that silver nanoparticles coated with
β-cyclodextrin (β-CD) are more efficient as SERS substrates when compared to the citrate-reduced
colloids. The authors of this study showed that the addition of β-CD improves sensitivity, time of
analysis, and the linear range of the SERS response, besides making the colloids more stable toward
aging. With these modified nanoparticles, 6-MP could be quantified in aqueous solutions with a LOD
of 2.4 nM and a limit of quantification of 0.8 nM.
Because of the chemical complexity of biofluids, as mentioned in Section 1.3, it might be useful
to combine SERS with separation techniques, such as thin layer chromatography (TLC). In a work
by our own research group [40], irinotecan at the concentration of 2.27 and 27.3 µM was detected in
water and in HSA solutions, respectively, after a combined deproteinization/separation step using
TLC. The irinotecan solution underwent a deproteinization and separation step on the TLC plate,
using a mixture of chloroform and methanol with the two-fold role of deproteinization solvent and
eluent. A drop of colloid was then deposited on the TLC plate where the drug was expected according
to a reference position (determined using pure irinotecan solutions). This approach, despite the
advantage of combining deproteinization and separation in a single step, still had poor repeatability,
related to the use of dried spots of metal colloids as substrates.
Other authors reported the use of a flow system to mix samples and colloidal substrates
to optimize nanoparticles aggregation for SERS detection, with the aim of increasing
repeatability [31,82,83]. In these approaches the metal colloids, the aggregating agents, and the
sample are pumped in a flow system (constituted by a macroscopic flow cell [45] or a microfluidic
system [77]), mixed at some point, and are then measured using a Raman microscope. A schematic
diagram of the flow system used in this study is shown in Figure 1.
In a pioneering work by McLaughlin et al. [45], which is still considered to be one of the most
successful SERS applications of drug quantification in biofluids, quantification of mitoxantrone in
real serum samples from patients was performed, showing an excellent correlation with a reference
method such as HPLC. Citrate-reduced silver colloids, activated (i.e., pre-aggregated) with NaCl or
poly-L-lysine, were used as the SERS substrate.
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Hidi et al. [80] used a similar approach, but based on a microfluidic system with a 
Lab-on-a-Chip set-up, to quantify methotrexate (MTX) in KOH solutions at pH ~12 with the use of 
silver colloid activated with KCl as the SERS substrate. As in the paper by McLaughlin et al. [45], in 
this work colloidal aggregation was controlled using a flow system. However, the feasibility of a 
microfluidic SERS chip for MTX quantitation was only demonstrated with model solutions, while its 
efficiency with more complex biofluids has yet to be tested. In general, controlled aggregation of the 
metal colloids using a flow system produced repeatable results, but at the cost of a more complex 
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a le 3. Sum ary of HPLC and SERS* Analysis Results for Patient Samples, reprinted with permission
fro ref. [45].
concentration of mitoxantrone (ng/mL)
Time HPLC SERS *
0 0 nd
5 3.1 2.9
10 1.9 1.0
15 252.3 247.3
20 186.9 183.2
30 53.7 54.1
45 23.7 20.3
60 11.6 9.2
90 9.4 8.9
120 6.2 6.0
180 5.7 4.8
240 1.8 1.0
360 3.2 3.0
720 1.8 1.3
* In this study, authors chose a laser frequency which is in resonance with the analyte, so they correctly defined
it as surface enhanced resonance Raman spectroscopy (SERRS) instead of SERS.
Hidi et al. [80] used a similar approach, but based on a microfluidic system with a Lab-on-a-Chip
set-up, to quantify methotrexate (MTX) in KOH solutions at pH ~12 with the use of silver colloid
activated with KCl as the SERS substrate. As in the paper by McLaughlin et al. [45], in this work
colloidal aggregation was controlled using a flow system. However, the feasibility of a microfluidic
SERS chip for MTX quantitation was only demonstrated with model solutions, while its efficiency with
more complex biofluids has yet to be tested. In general, controlled aggregation of the metal colloids
using a flow system produced repeatable results, but at the cost of a more complex (and perhaps more
expensive) setup.
Biosensors 2016, 6, 47 9 of 17
Interesting quantitative applications of SERS of drugs were also reported for samples other than
biofluids. For instance, Han et al. [84] reported the monitoring of metabolism of 6-MP in living
cells. It turned out that after being uptaken into cells, gold nanoparticles conjugated to 6-MP were
metabolized to 6-MP-ribose after 4 h and the signal drastically decreased after 16 h. A similar label-free
approach for the SERS quantification of 6-MP in HeLa cells was also reported by Yang et al. [85].
Although not directly aimed at quantification, these papers show how quantitative SERS can also be
applied to study drug metabolism in living biological systems.
2.2. Non-Colloidal Substrates
Without the problems due to colloidal stability, non-colloidal substrates offer much more
possibilities for the chemical functionalization of metal surfaces with recognition elements. Such surface
modifications allow for an increase in repeatability, an improvement in the analyte signal due to
an increased drug concentration near the metal, as well as a more straightforward procedure, avoiding
the handling of the colloidal substrates and their mixing with the analyte.
In recent years, the number of papers involving the preparation of new non-colloidal SERS
substrates is rapidly increasing [86]. The large number and variety of substrates reported in the
literature shows the growing interest in this topic, as well as the lack of consensus about what substrate
performs better. This is caused, among other factors, by the fact that different molecules interact with
substrates in a variety of ways, so that perhaps a “universal” SERS substrate, which can be generally
applied to all analytes, is just an abstract concept. Indeed, different kinds of non-colloidal substrates
have been used for the detection of TDM drugs, with different outcomes.
KlariteTM substrates were commercially available gold-coated nanostructured silica surfaces
distributed by Renishaw Diagnostics Ltd. In a recent work by Litti et al. [79], methanol solutions of
sunitinib, paclitaxel, irinotecan, SN-38 (a metabolite of irinotecan), and doxorubicin (as reference) were
deposited on the KlariteTM substrates and dried in air at room temperature. Apart from paclitaxel,
the other drugs were quantified at therapeutic concentrations using a univariate approach. This work
clearly showed the feasibility of SERS quantification of these drugs, although in simple model solutions,
without the complications due to the complexity of real biofluids. In this article, authors also remarked
that while the density of hot spots is crucial for the determination of the limit of quantification,
the homogeneity with which such hot spots are distributed onto the surface is related to repeatability:
both these aspects are important while designing new SERS substrates.
Another promising type of solid SERS substrate employed for drug quantification with SERS
was recently obtained using UV-assisted nano-imprint lithography (UV-NIL) [81]. With this substrate,
the authors reported SERS spectra of water solutions of paclitaxel down to nanomolar concentrations.
UV-NIL substrates were covered with a monolayer of BSA, which in this case was used as a recognition
element for binding the drug close to the metal. The SERS intensity of a band in the C-H stretching
region showed a linear dependence on the concentration of paclitaxel between 1.2 × 10−9 M and
11.9 × 10−6 M. The authors of this study remarked that the LOD obtained with this approach was
similar to that achieved with LC-MS-MS, and a hundred times lower than that reported for HPLC.
As for the previous example, this paper shows promising results with simple model solutions,
far simpler than real biofluid samples, in which albumin and other proteins as well are already present.
Yuen et al. [72] reported the quantification of paclitaxel in blood plasma with the use of
gold-polystyrene beads as SERS substrates and a multivariate calibration based on PLS. Polystyrene
beads were deposited on a microscope glass slide by using a sedimentation technique, covered
with a 15 nm-thick gold film and heated with microwaves. SERS spectra were measured at the
concentration range from 1.0 × 10−8 M to 1.0 × 10−7 M, which according to the authors is comparable
to the concentration detected by more time-consuming reference methods such as HPLC.
Nanoparticles deposited on filter paper are yet another example of a non-colloidal SERS substrate
obtained with a bottom-up approach [54], which is possibly one of the less expensive substrates among
the non-colloidal ones. MTX could be quantified in model solutions with HSA as well as spiked diluted
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human serum, resulting in a good linear SERS response in the concentration range of 1.0 × 10−7 M to
3.0 × 10−4 M, thus covering the therapeutic range of the drug (Figure 2).
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Imatinib, another anti-cancer drug for which TDM is deemed useful, was successfully determined
at concentrations of 0.1, 0.005, and 0.001 mg/mL (2 × 10−6 M–2 × 10−4 M) in plasma [71], using
gold nanoparticles deposited on aluminum-covered glass slides as SERS substrates. This study was
considered by the authors themselves as a “proof of concept”, and did not provide any calibration or
other figures of merit (e.g., LOD, LOQ, etc.), but demonstrated that this drug could be observed with
SERS at clinically relevant concentrations.
Gr phene-modified met l nanostructures, already reported as colloidal substrates, were also
used s non-colloidal substra es by Li et al. [76], who qua titatively determined MTX and some
polar antibiotics n w ter in the range of 10−9 M–10−3 M using AgNPs—graphene nanocomposites
deposited on disposable scree -printed electrodes. This paper exploited th larity of these drugs to
increase their concentration at the SERS substrates by varying the surface potential. The potential that
was applied had a marked effect on both spectral shape and intensity, and with adequate potentials,
MTX could be quantified with a LOD of 0.6 nM.
Flow systems, which were successfully used to control aggregation kinetics, thus improving
repeatability, with colloidal substrates [45,80] can also be used with non-colloidal SERS substrates,
provided that the methods allow for a substrate regeneration for multiple uses. In a recent work by
Wu and Cunningham [77], 10 pharmaceutical compounds (including mitoxantrone) were measured
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in aqueous solutions using a flow-cell system. Plasmonic nanodome array structures, fabricated
using a “nanoreplica molding process” on flexible plastic sheets, were used as SERS substrates.
Upon flowing different solutions onto this substrate, several drugs could be detected at clinically
relevant concentrations. SERS detection was shown to be almost reversible so that flushing the substrate
with DI water caused the SERS signal to disappear almost entirely. This approach was demonstrated
to be repeatable, and quantification was shown to be possible with a univariate approach, yielding
a LOD of 18.6 ng/mL (~4.18 × 10−8 M) for mitoxantrone.
SERS detection and quantification of drugs were also achieved using innovative non-colloidal
substrates, designed to be directly used as sample collection tools, with the aim of a faster and easier
analysis. Sample collection or handling tools such as needles [69] or capillaries [67] were modified
with metal nanoparticles to work as SERS substrates. The idea is very interesting since it could
enable sample collection directly from the patient, allowing a direct SERS measurement. Up to
now, the results reported in the literature are still preliminary, although very promising and worth
developing. Dong et al. [69] reported the in vivo detection of 6-MP: SERS-active needles were inserted
into a rabbit ear vein and vastus lateralis tendon for 10 min to detect the drug concentration in blood
and muscles, respectively. The structure of the needle is shown in Figure 3. The main problem with this
approach, so far, is that the quantitative analysis was problematic because of difficulties in controlling
the volume of the blood in the needle. Despite the fact that no calibration curve or other FOMs
were reported, this paper shows that a fast, real-time in vivo quantitative determination with SERS is
feasible and that further investigation in this direction is certainly worth pursuing.
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A similar approach with nanoparticle-modified capillaries was also reported with biofluids other
than blood. Farquharson et al. [67] performed SERS measurements of 5-fluoro uracil (5-FU) in saliva
with the use of SERS-active capillaries, internally coated with a layer of silver-doped sol–gel. The aim
of the experiment was to reduce the time of the analysis (to 5 min) and the amount of saliva (<1 mL),
with respect to other methods. With these SERS-active capillaries, it was possible to measure 5-FU at
the concentration of 2 µg/mL in water and 500 µg/mL in saliva (1.54 × 10−5 M and 3.8 × 10−3 M,
respectively). Again, the authors did not present any calibration plot, or any FOM (they estimated
a “limit of detection”, but in the absence of a calibration). In spite of these methodological issues
concerning quantification, since the toxicity of 5-FU was correlated with drug levels above 3 mg/L
(2.3 × 10−5 M) [87], the methodology needs to be improved for a successful application in TDM.
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2.3. Hybrid Substrates
In some cases, SERS detection was achieved using a so-called “sandwich” strategy, making use
of two different substrates in a hybrid method, with the aim of trapping the analyte in between the
different metal nanostructures [88]. In a recent work by Yang et al. [73], folic acid (FA) and MTX were
trapped between a two layers of silver nanoparticles. To show the advantage of this sandwich strategy
over common substrates, reference measurements were performed using silver nanoparticles only.
With this approach it was possible to detect both FA and MTX in the presence of bovine serum albumin
at a concentration of 10−9 M. Despite the fact that it was only demonstrated for simple model solutions,
the detection of such a low concentration of a drug points to the potential of this approach in terms of
sensitivity. On the other hand, such a method, involving the application of two different substrates at
separate steps, appears to be more complicated to apply, making it less suitable for point-of-care tests.
3. Conclusions and Perspectives
Although in recent years an increase in the number of papers in this field has been observed,
publications about SERS applied to TDM are still relatively few, and no definite methodological trend is
present. In our opinion, this is a direct consequence of the many difficulties and challenges encountered
when the quantification of drugs is pursued with SERS in complex samples such as biofluids.
The studies published so far clearly demonstrate the potential of SERS for TDM, as many of
them reported the feasibility of quantification at clinically-relevant concentrations, but most of these
studies were carried out in model solutions, far simpler than real biofluids such as plasma or serum.
In fact, only one example of the application to real clinical samples (i.e., serum of patients treated
with mitoxantrone) has been published, and SERS showed an analytical performance comparable
to HPLC [45]. Other drugs for which TDM is deemed relevant have been successfully quantified
only in spiked biofluids (6-mercaptopurine [69], doxorubicin [70], imatinib [71], methotrexate [54],
mitoxantrone [45], and paclitaxel [72]). All of the other studies considered buffered solutions of drugs,
sometimes in the presence of serum proteins such as HSA. The role and impact of the chemical
complexity of biofluids on SERS have been already addressed in Section 1.3, and, likely, more
fundamental and methodological studies on biofluid-metal interactions are needed to better tackle
this issue.
Thus, in spite of its potential to advance individualized care and reduce the associated healthcare
costs, SERS technology has not yet reached the maturity for routine analysis, and several key challenges
need to be addressed before it can be adopted in clinical practice.
Figure 4 schematically depicts the roadmap for a clinical translation process, including
the Technology Readiness Levels (TRL) that are typically used to assess the maturity of novel
technologies [89]. Current research for the implementation of SERS as a tool for TDM is at an early
stage, as most of the studies have been focused on substrate development and evaluation in simple
solvents/surrogate matrices (TRL 2–3 and 4), with only one study mentioned above reporting the
analysis of real samples (TRL 5). Although more studies on real samples are needed for the use in
clinical practice (TRL 9), progress has been substantial.
The foremost challenge, which is a general problem in SERS going beyond TDM applications, is the
development of “standardized” substrates (and thus of standard definitions, guidelines, and protocols)
that, with adequate adaptations, can be generally used for the detection of different molecules/groups
of molecules. For TDM, which involves quantitative analysis, this aspect is even more crucial than for
other applications. So far, each research group has used its own SERS substrates, prepared according
to different protocols: only in a few publications was the same substrate applied to more than one
drug. The availability of commercial, repeatable, and standardized SERS substrates at reasonable
prices is thus a pre-requisite for the application of SERS outside academic and institutional research
centers. We believe this is particularly true for clinical applications, which are strictly regulated by
national laws.
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are two of the most critical problems to be solved, either by efficient and fast de-proteinization and
separation steps or by surface functionalization with selective recognition elements. Both strategies
should aim for the simplification of the biofluid complexity at the surface of the SERS substrate.
A third challenge involves the correct use of data analysis and calibration methods, as well as
a proper estimation of important FOMs, such as LODs and LOQs. In fact, for the majority of the
literature considered in this review, FOMs are often reported only partially and/or are not properly
defined. As an example of this, only one of the considered studies used the official IUPAC definition
for the LOD calculation, while nine out of fifteen studies did not even report the LOD for the method
(Table 2). This is especially important in view of clinical applications, where analytical methods
should comply with formal guidelines. Moreover, the potential of multivariate calibration methods,
which are especially useful in recognizing the SERS signal of the analyte from the fluctuations due to
the interindividual variability intrinsic to biofluids, has not yet been fully exploited.
Last but not least, a SERS-based method for TDM should be developed that considers several
characteristics required for a routine use in a clinical setting, such as robustness (i.e., it should not
involve too delicate or complex instrumentation), cost (it should be competitive with respect to the
available methods), ease of use (it should be easy to operate by non-specialized users) and ease of the
interpretation of results (it should give a response in terms of concentration and error). Many papers,
even those that presented very promising results, sometimes did not consider or discuss these issues.
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